Diabetic Macular Edema/Diabetic Retinopathy | Unmet Need | Diabetic Macular Edema | US/FR/DE/UK | 2021
Diabetic macular edema (DME) represents the second-largest ophthalmology market for intravitreal anti-VEGF therapies, including Roche / Novartis’s Lucentis and Regeneron / Bayer’s market-leading Eylea. Because these therapies require regular injections to be effective, they present a major delivery burden that often impacts patient compliance. The corticosteroid implants Ozurdex (AbbVie) and Iluvien (Alimera Sciences) provide a longer duration of action between doses but are associated with side effects that relegate them to later-line treatment. Therefore, unmet need remains for therapies that provide strong efficacy for improving visual acuity with less-frequent dosing.
QUESTIONS ANSWERED
- What are the key treatment drivers and goals for DME that influence ophthalmologists’ choice of therapies?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities in the DME market?
- How do ophthalmologists perceive the performance of current therapies on key treatment drivers and goals for DME?
- What are the prevailing areas of market opportunity in the treatment of DME? Will emerging therapies, such as Novartis’s Beovu or Roche’s faricimab, fulfill these unmet needs?
- What trade-offs are acceptable to U.S. and European ophthalmologists for a hypothetical DME drug?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European ophthalmologists fielded in February 2021
Key companies: Roche / Genentech, Regeneron / Bayer, Novartis, AbbVie (Allergan), Alimera Sciences, Kodiak Sciences
Key drugs: Lucentis, Eylea, Avastin, Ozurdex, Iluvien, Beovu, ranibizumab port delivery system, high-dose aflibercept, KSI-301, faricimab
